Dasatinib tyrosine kinase inhibitor as second and third line therapy in chronic myeloid leukemia: outcome of a Nepalese study. (2018). Journal of Patan Academy of Health Sciences, 5(1), 47-56. https://doi.org/10.3126/jpahs.v5i1.24042